Cargando…
Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551237/ https://www.ncbi.nlm.nih.gov/pubmed/28718828 http://dx.doi.org/10.3390/ijerph14070799 |
_version_ | 1783256274833506304 |
---|---|
author | Bell, Stephanie Dean, Judith Gilks, Charles Boyd, Mark A. Fitzgerald, Lisa Mutch, Allyson Baker, Peter Neilsen, Graham Gartner, Coral E. |
author_facet | Bell, Stephanie Dean, Judith Gilks, Charles Boyd, Mark A. Fitzgerald, Lisa Mutch, Allyson Baker, Peter Neilsen, Graham Gartner, Coral E. |
author_sort | Bell, Stephanie |
collection | PubMed |
description | Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations. |
format | Online Article Text |
id | pubmed-5551237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55512372017-08-11 Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke Bell, Stephanie Dean, Judith Gilks, Charles Boyd, Mark A. Fitzgerald, Lisa Mutch, Allyson Baker, Peter Neilsen, Graham Gartner, Coral E. Int J Environ Res Public Health Concept Paper Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations. MDPI 2017-07-18 2017-07 /pmc/articles/PMC5551237/ /pubmed/28718828 http://dx.doi.org/10.3390/ijerph14070799 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Concept Paper Bell, Stephanie Dean, Judith Gilks, Charles Boyd, Mark A. Fitzgerald, Lisa Mutch, Allyson Baker, Peter Neilsen, Graham Gartner, Coral E. Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title | Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title_full | Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title_fullStr | Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title_full_unstemmed | Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title_short | Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke |
title_sort | tobacco harm reduction with vaporised nicotine (thrive): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with hiv who smoke |
topic | Concept Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551237/ https://www.ncbi.nlm.nih.gov/pubmed/28718828 http://dx.doi.org/10.3390/ijerph14070799 |
work_keys_str_mv | AT bellstephanie tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT deanjudith tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT gilkscharles tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT boydmarka tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT fitzgeraldlisa tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT mutchallyson tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT bakerpeter tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT neilsengraham tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke AT gartnercorale tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke |